X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/jj-latest-data-nipocalimab-fetal-disorder-suggests-momenta-buy-may-pay
https://www.business-standard.com/article/companies/j-j-momenta-pharma-file-patent-infringement-lawsuit-against-natco-mylan-122052500935_1.html
https://www.fiercebiotech.com/biotech/provention-bio-hires-third-exec-as-many-weeks-as-it-awaits-fda-meeting-for-rejected-drug
https://www.fiercebiotech.com/biotech/j-j-free-from-rival-bidders-made-momenta-wait-6-5b-deal
https://endpts.com/enthused-by-phii-autoimmune-data-jj-kept-momenta-waiting-in-the-lead-up-to-6-5b-buyout/
https://www.globenewswire.com/news-release/2020/07/28/2068533/0/en/Momenta-Pharmaceuticals-Announces-FDA-Rare-Pediatric-Disease-Designation-for-Nipocalimab-in-HDFN.html#:~:text=(NASDAQ%3A%20MNTA)%20today%20announced,orphan%20drug%20designation%20in%20HDFN.
https://endpts.com/momenta-clears-a-phii-hurdle-on-nipo-but-one-big-rival-remains-well-in-the-lead-in-this-packed-field/
https://www.momentapharma.com/investors-and-news/press-releases/press-releases-details/2020/Momenta-Pharmaceuticals-Announces-Positive-Topline-Data-from-Interim-Analysis-of-Phase-2-Vivacity-MG-Study-of-Nipocalimab-M281-in-Generalized-Myasthenia-Gravis-gMG/default.aspx
Market Place
Share 
